5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for fat loss and metabolic effects. NNMT is overexpressed in adipose (fat) tissue in obese individuals and is sometimes called the 'obesity enzyme.' By inhibiting NNMT, 5-Amino-1MQ theoretically raises cellular NAD+ and SAM levels, boosting metabolism in fat cells.

How does 5-Amino-1MQ cause fat loss?

NNMT consumes SAM (S-adenosylmethionine) and produces 1-methylnicotinamide. In fat tissue, high NNMT activity depletes SAM and NAD+ precursors, reducing metabolic rate. 5-Amino-1MQ inhibits NNMT, which: raises SAM levels (needed for epigenetic methylation), restores NAD+ pathway flux, and increases energy expenditure in adipocytes. In mouse models, NNMT-inhibited mice ate the same but gained significantly less fat.

What does the research show for 5-Amino-1MQ?

Published research (Kannt et al., 2018, PMID: 29534932) showed 5-Amino-1MQ reduced body weight and fat mass in high-fat diet mouse models without changes in food intake. Another study (Neelakantan et al., 2019) showed NNMT inhibition reduced adiposity and improved metabolic parameters. These are preclinical studies — no human trials have been published.

What is the typical 5-Amino-1MQ dose?

Research compound dosing is extrapolated from animal studies. Community protocols typically use 50-150mg per day, orally. Some protocols use 50mg twice daily. 5-Amino-1MQ is orally bioavailable. There are no established human clinical doses — all human use is off-label extrapolation from mouse study doses scaled by body weight.

Safety data is very limited. Preclinical mouse studies showed no obvious toxicity. No human safety trials have been published. The mechanism (NNMT inhibition affecting NAD+ and SAM metabolism) could potentially affect epigenetic processes throughout the body. Long-term effects are unknown. Use with caution — this is an early-stage research compound with minimal human safety data.

Fat Loss Research · NNMT Inhibitor · Metabolic Compound

5-Amino-1MQ: Targeting the "Obesity Enzyme" for Fat Loss

By HighPeptides Research Team

Last updated: April 2026

5-Amino-1MQ is one of the most mechanistically interesting fat loss compounds in the research space. It inhibits NNMT — an enzyme overexpressed in obese adipose tissue that acts as a metabolic brake. In mouse models, NNMT inhibition produced significant fat loss without reduced food intake. No human trials yet, but the mechanism is compelling.

NNMT

Target Enzyme
Nicotinamide N-methyltransferase — the "obesity enzyme"

Oral

Bioavailability
Unlike most fat loss peptides — orally active

NAD+

Downstream Effect
Raises NAD+ and SAM in adipose tissue

Mechanism of Action

How NNMT Inhibition Drives Fat Loss

The mechanism is elegant: block an enzyme that fat cells use to suppress their own metabolism. Remove the brake — the cells burn more energy.

🔴

What NNMT Does (The Problem)

NNMT (nicotinamide N-methyltransferase) consumes SAM (S-adenosylmethionine) to methylate nicotinamide, producing 1-methylnicotinamide. This depletes SAM and drains NAD+ precursors. In obese adipose tissue, NNMT is upregulated 3-5x vs. lean tissue. The result: metabolically suppressed fat cells that resist energy expenditure. NNMT becomes a metabolic governor locking in obesity.

✅

What NNMT Inhibition Does (The Solution)

5-Amino-1MQ inhibits NNMT, stopping SAM depletion. Restored SAM supports epigenetic methylation (including PCSK9 promoter methylation — reducing LDL cholesterol). Restored NAD+ precursor flux supports sirtuin activity and mitochondrial biogenesis in fat cells. The net effect: adipocytes resume normal energy expenditure. In Neelakantan et al. (2019), treated mice showed reduced fat mass with identical food intake.

⚡

NAD+ and Sirtuin Activation

NAD+ is required for SIRT1, SIRT3, and other sirtuins — metabolic enzymes that regulate energy expenditure, fatty acid oxidation, and mitochondrial function. By restoring NAD+ precursor availability, NNMT inhibition indirectly boosts sirtuin activity. This overlaps mechanistically with NMN/NAD+ supplementation but acts specifically in adipose tissue rather than systemically.

📉

Lipid Profile Effects

Restored SAM enables methylation of the PCSK9 gene promoter, reducing PCSK9 expression. PCSK9 degrades LDL receptors in the liver — inhibiting PCSK9 is the mechanism of action of expensive PCSK9 inhibitor drugs. Neelakantan et al. (2019, PMID: 31471598) showed 5-Amino-1MQ treated mice had significantly reduced LDL-C alongside reduced adiposity. A dual fat loss + LDL reduction effect.

Evidence Review

What the Research Shows

Preclinical evidence is compelling. Human evidence is absent. The gap between mouse studies and human outcomes is a critical caveat.

NNMT Inhibition (in vitro)

Confirmed potent NNMT inhibitor — IC50 well-characterized

Very Strong

Fat Mass Reduction (Mouse HFD Models)

Neelakantan et al. 2019 (PMID: 31471598) — significant adiposity reduction

Strong

LDL-C Reduction (Mice)

PCSK9 methylation pathway — significant LDL reduction in treated mice

Strong (preclinical)

Human Clinical Evidence

No published human trials — community reports only

None

Safety

Side Effects & Safety Concerns

Very limited human safety data. Mouse study safety appeared favorable, but SAM/NAD+ pathway effects systemically have unknown long-term implications.

GI Discomfort (community reports)

Nausea, loose stools — common at start of protocol

~20%

Headache (initial)

First 1-2 weeks — may relate to SAM/methylation changes

~12%

Increased Energy / Warmth

Reported by community as positive effect — thermogenic signal

~30%

Serious / Systemic Adverse Events

None confirmed in mice or community reports — unknown in humans long-term

Unknown

Summary

Key Takeaways

✅ What We Know

Potent, well-characterized NNMT inhibitor in vitro
Mouse HFD studies show significant fat mass reduction (PMID: 31471598)
LDL reduction via PCSK9 methylation is an interesting secondary effect
Orally bioavailable — unlike most fat loss peptides (no injection required)
SAM/NAD+ restoration mechanism is mechanistically sound and published

⚠️ What We Don't Know

No human clinical trials published — all efficacy data is preclinical
Mouse-to-human translation for NNMT inhibition is unproven
Long-term systemic SAM/NAD+ pathway effects are unknown
NNMT inhibition in non-adipose tissues may have unintended effects
Optimal human dose is extrapolated — not established by human pharmacokinetics

5-Amino-1MQ: Targeting the "Obesity Enzyme" for Fat Loss

How NNMT Inhibition Drives Fat Loss

What the Research Shows

Side Effects & Safety Concerns

Key Takeaways

🔬 Research-Grade Peptides

Swiss Chems

Evidence-Based Metabolic Supplements

5-Amino-1MQ: Targeting the "Obesity Enzyme" for Fat Loss

How NNMT Inhibition Drives Fat Loss

What the Research Shows

Side Effects & Safety Concerns

Key Takeaways

Related Fat Loss Compounds

🔬 Research-Grade Peptides

Swiss Chems

Evidence-Based Metabolic Supplements